Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings.

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[3]  V. Roger.  Epidemiology of Heart Failure , 2013, Circulation research.

[4]  M. Redfield,et al.  Acute Heart Failure with Preserved Ejection Fraction: Unique Patient Characteristics and Targets for Therapy , 2013, Current Heart Failure Reports.

[5]  D. McManus,et al.  Improved Survival After Heart Failure: A Community‐Based Perspective , 2013, Journal of the American Heart Association.

[6]  Geoffrey D. Mills,et al.  Heart failure: Best options when ejection fraction is preserved. , 2013, The Journal of family practice.

[7]  J. McMurray,et al.  What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? , 2012, Journal of the American College of Cardiology.

[8]  Shannon M. Dunlay,et al.  Longitudinal Changes in Ejection Fraction in Heart Failure Patients With Preserved and Reduced Ejection Fraction , 2012, Circulation. Heart failure.

[9]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[10]  Robert N. Doughty,et al.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.

[11]  J. Fang,et al.  Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? , 2011, Mayo Clinic proceedings.

[12]  J. Gore,et al.  Clinical Features, Treatment Practices, and Hospital and Long‐Term Outcomes of Older Patients Hospitalized with Decompensated Heart Failure: The Worcester Heart Failure Study , 2009, Journal of the American Geriatrics Society.

[13]  J. Saczynski,et al.  Epidemiology of decompensated heart failure in a single community in the northeastern United States. , 2009, The American journal of cardiology.

[14]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[15]  Margarita Lopatin,et al.  Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. , 2008, The American journal of cardiology.

[16]  M. Cheitlin,et al.  Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study , 2008 .

[17]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[18]  R. Goldberg,et al.  Long-term survival after heart failure: a contemporary population-based perspective. , 2007, Archives of internal medicine.

[19]  R. Goldberg,et al.  Use of disease-modifying therapies in patients hospitalized with heart failure: a population-based perspective. , 2007, The American journal of medicine.

[20]  N. Freemantle,et al.  FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .

[21]  Ali Ahmed,et al.  Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial , 2006, Circulation.

[22]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[23]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[24]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[25]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[26]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[27]  R. Vasan,et al.  Defining diastolic heart failure: a call for standardized diagnostic criteria. , 2000, Circulation.

[28]  H. Black,et al.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. , 1990, The American journal of cardiology.

[29]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.